Company intelligence
VectorY
VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions.
About VectorY
VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need. By combining state-of-the-art technologies and novel and scientific concepts, VectorY’s mission is to bring innovative therapies to patients worldwide. Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases. With R&D and manufacturing facilities in Amsterdam, VectorY develops proprietary & partnered programs based on its novel AAV-based vectorized antibody & gene therapy platform. Product candidates are based on new vector technologies, which will enable the next generation of highly scalable manufacturing processes within VectorY’s own manufacturing facilities. Our manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply.
Verified activity
Signals from VectorY
7 published signals
Presence & Recognition
VectorY congratulated participants Barbara Sanders, Lilly Burggraaf, Jim Scibetta, Andreia Duarte, Marina Koning, Sophie Shrimpton, Andrey Larionov, and Olga Uspenskaya-Cadoz for completing the Amsterdam City Swim event.
Reported by VectorY
Presence & Recognition
VectorY participated in the Amsterdam City Swim exhibit at the September 6 Amsterdam City Swim event.
Reported by Jim Scibetta
Presence & Recognition
VectorY is participating in the Amsterdam City Swim challenge, a swim through Amsterdam's canals bringing people together to raise funds for ALS research.
Reported by VectorY
People
VectorY welcomed Alida Chen, Andrey Larionov, Koen Wagner, Mels Schrama, and Alexine van Karnebeek as new joiners.
Reported by VectorY
Presence & Recognition
VectorY noted that Leonard van den Berg L mentioned the first dosing of the first European participant of the PIONEER-ALS study at UMC Utrecht.
Reported by VectorY
Partnerships
VectorY has been a partner to the UMCU team and Dr. van den Berg since the company's founding 6 years ago.
Reported by Jim Scibetta
Research & Knowledge
VectorY completed the dosing of the first European participant in the Phase 1/2 PIONEER-ALS study, occurring only ~50 kilometers from the birthplace of both VectorY and VTx-002.
Reported by Barbara Sanders